77 results
S-8
EX-4.2
VKTX
Viking Therapeutics Inc
22 May 24
Registration of securities for employees
4:33pm
of the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the members of the Board; provided, however … , that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
reductions in body weight compared with placebo. Additionally, the study showed VK2735 treatment to be safe and well tolerated, with the majority … the 13 week treatment period of this study.
VK2735 also demonstrated encouraging safety and tolerability in the VENTURE study, with the majority
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
to date have been mild or moderate, with the majority (76%) reported as mild. Similarly, all observed gastrointestinal (GI) adverse events have been … reported as mild or moderate, with the majority (79%) reported as mild. Mild nausea was reported in five (14%) VK2735-treated subjects. Vomiting
424B5
pa497qxm
1 Mar 24
Prospectus supplement for primary offering
4:13pm
424B5
j8c 349bkjar3r7zpi76
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
pz2bw4bca
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
ecdo944ls7krbzn
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
z143uvzupvuup9smg mo
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
i0ac1k3b7l8vm8b 49
26 Jul 23
Automatic shelf registration
5:26pm
S-3ASR
EX-4.2
3gg6 aazf1ybpgg7olvc
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
b7q4pfibx4atn
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-3.1
i5ope
11 May 23
Amendments to Articles of Incorporation or Bylaws
5:00pm
8-K
EX-99.1
v1a9 k42jqnjv0i
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm